Therefore, it is imperative to update the previous paradigm of EGFR mutation testing to middle‐aged, middle‐eastern, nonsmoker females should be updated to all NSCLC patients as major advancements in targeted therapy and patient survival among NSCLC patients harboring EGFR mutations have been achieved in recent years.37 Here, EGFR is linked to non-small cell lung carcinoma.